Newsroom

BLUE BELL, Pa.--(BUSINESS WIRE)--This October, a familiar sight across thousands of properties nationwide will take on a new color: pink. For the third consecutive year, BrightView (NYSE: BV), the nation’s leading commercial landscaping company, is bringing its team members together to support Breast Cancer Awareness Month. Throughout October, BrightView employees will wear specially designed pink hats as they care for landscapes, maintain properties, and serve communities across the country. T...

MILWAUKEE--(BUSINESS WIRE)--Mayville Engineering Company (NYSE: MEC) (the “Company” or “MEC”), a leading value-added provider of design, prototyping and manufacturing solutions serving diverse end-markets, today announced an expansion of its Southeastern U.S. manufacturing footprint through the acquisition of a 138,000 square foot finishing facility in Thomson, Georgia. The transaction closed on October 1, 2026. The Company expects to invest in phases a total of approximately $25 million to $30...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

GALASHIELS E MARLOW, REINO UNIDO--(BUSINESS WIRE)--A Kyowa Kirin International, subsidiária integral da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), anunciou hoje a assinatura de um contrato de distribuição exclusiva com a Knight Therapeutics (“Knight”) (TSX: GUD) para distribuição de mogamulizumabe em países selecionados da América Latina. Nos termos do contrato, a Knight será responsável por obter as aprovações regulatórias necessárias e comercializar o mogamulizumabe para micose fungoide (...

GALASHIELS e MARLOW, Regno Unito--(BUSINESS WIRE)--Kyowa Kirin International, società interamente controllata da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), oggi ha annunciato la firma di un accordo di distribuzione esclusiva con Knight Therapeutics (“Knight”) (TSX: GUD) per la distribuzione di mogamulizumab in determinati Paesi dell'America Latina. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unic...

GALASHIELS y MARLOW, Reino Unido--(BUSINESS WIRE)--Kyowa Kirin International, subsidiaria de propiedad absoluta de Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), anunció hoy la firma de un acuerdo exclusivo de distribución con Knight Therapeutics (“Knight”) (TSX: GUD) para comercializar mogamulizumab en determinados países de América Latina. En virtud del acuerdo, Knight será responsable de obtener las autorizaciones regulatorias necesarias y de comercializar mogamulizumab para el tratamiento...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 30.09.2026 FTEI.LN IE000TIZ5AP4  300,002.00 EUR   6,200,335.39   20.668  ...

GALASHIELS & MARLOW, VK--(BUSINESS WIRE)--Kyowa Kirin International, een volledige dochteronderneming van Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), heeft vandaag de ondertekening aangekondigd van een exclusieve distributieovereenkomst met Knight Therapeutics ('Knight') (TSX: GUD) voor de distributie van mogamulizumab in geselecteerde landen in Latijns-Amerika. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden ver...

GALASHIELS et MARLOW, Royaume-Uni--(BUSINESS WIRE)--Kyowa Kirin International, filiale à 100 % de Kyowa Kirin Co., Ltd. (TSE : 4151, Kyowa Kirin), a annoncé aujourd’hui avoir signé un accord de distribution exclusif avec Knight Therapeutics (« Knight ») (TSX : GUD) portant sur la distribution du mogamulizumab dans certains pays d’Amérique latine. Selon les termes de l’accord, Knight aura pour mission d’obtenir les autorisations réglementaires nécessaires pour commercialiser le mogamulizumab en...

GALASHIELS & MARLOW, GB--(BUSINESS WIRE)--Kyowa Kirin International, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die Unterzeichnung einer exklusiven Vertriebsvereinbarung mit Knight Therapeutics („Knight“) (TSX: GUD) über den Vertrieb von Mogamulizumab in ausgewählten Ländern Lateinamerikas bekannt. Gemäß den Vertragsbedingungen ist Knight dafür verantwortlich, die erforderlichen behördlichen Genehmigungen einzuholen und Mogamulizumab...